SA pharmaceutical journal., Journal Year: 2024, Volume and Issue: 91(6), P. 31 - 34
Published: Dec. 1, 2024
Language: Английский
British Journal of Pharmacology, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 13, 2025
Obesity is a complex and growing global concern, affecting one in eight individuals compromising health, quality of life expectancy. It carries significant metabolic, cardiovascular, oncological, hepatorenal, skeletal psychiatric risks, imposing substantial costs on health‐care systems. Traditional treatments have often been ineffective or led to relapse after lifestyle changes. Whereas bariatric surgery effective, it also involves risks such as mortality hospitalisation. Semaglutide, licensed 2018, synthetic analogue glucagon‐like peptide 1 which regulates glucose metabolism gastrointestinal (GI) motility. Studies show that semaglutide, administered either weekly subcutaneously, daily orally, induces an average weight loss −11.62 kg compared placebo reduces waist circumference by up −9.4 cm. improves blood pressure, fasting levels, C‐reactive protein levels lipid profiles. The most common adverse events are mild‐to‐moderate GI complaints occurring more frequently with administration than doses; hypoglycaemia without intervention. Weight regain follows semaglutide withdrawal. Furthermore, offers cardiovascular benefits for patients established atherosclerotic disease (CVD), lowers the risk kidney outcomes cardiovascular‐related death, resolves nonalcoholic steatohepatitis many cases, positively impacts mental health life. In conclusion, therapy could significantly benefit adults regarding CVD if made widely accessible. Ethical financial considerations must be addressed personalised obesity treatment approaches.
Language: Английский
Citations
3
Published: Feb. 20, 2025
The popularization of science, while essential for making complex discoveries accessible to the public, carries significant risks, particularly in healthcare where misinformation can lead harmful behaviors and even lethal outcomes. This commentary examines dual nature science communication, highlighting its potential foster public engagement scientific literacy also discussing dangers oversimplification sensationalism. Historical contemporary case studies, such as misrepresentation ivermectin during COVID-19 pandemic enduring "5-Second Rule" myth, illustrate how distorted findings erode trust institutions fuel conspiracy theories. digital age exacerbates these issues, with algorithms social media amplifying at an unprecedented scale. discussion emphasizes heightened stakes medical directly endanger lives. It calls a balanced approach popularization, advocating transparency, interdisciplinary collaboration, education combat misinformation. extends emerging role artificial intelligence healthcare, warning against inflated claims risks overreliance on unverified AI tools. Ultimately, this underscores need systemic reforms ensure that communication prioritizes accuracy, fosters critical thinking, builds resilience spread pseudoscience disinformation.
Language: Английский
Citations
3
Published: Feb. 6, 2025
The popularization of science, while essential for making complex discoveries accessible to the public, carries significant risks, particularly in healthcare where misinformation can lead harmful behaviors and even lethal outcomes. This commentary examines dual nature science communication, highlighting its potential foster public engagement scientific literacy also discussing dangers oversimplification sensationalism. Historical contemporary case studies, such as misrepresentation ivermectin during COVID-19 pandemic enduring "5-Second Rule" myth, illustrate how distorted findings erode trust institutions fuel conspiracy theories. digital age exacerbates these issues, with algorithms social media amplifying at an unprecedented scale. discussion emphasizes heightened stakes medical directly endanger lives. It calls a balanced approach popularization, advocating transparency, interdisciplinary collaboration, education combat misinformation. extends emerging role artificial intelligence healthcare, warning against inflated claims risks overreliance on unverified AI tools. Ultimately, this underscores need systemic reforms ensure that communication prioritizes accuracy, fosters critical thinking, builds resilience spread pseudoscience disinformation.
Language: Английский
Citations
2
Endocrinology Diabetes & Metabolism, Journal Year: 2025, Volume and Issue: 8(2)
Published: March 1, 2025
ABSTRACT Aims GLP‐1 receptor agonists, such as semaglutide (Ozempic) and tirzepatide (Monjaro), have gained significant popularity for obesity management, but concerns arisen about their potential link to thyroid cancer. This study investigates the association between cancer weight‐loss medications. Materials Methods A disproportionality analysis was conducted using data from FDA Adverse Event Reporting System (FAERS) 2004 Q1 2024. odds ratios (RORs) were used identify associations drugs, including anti‐diabetic Results Significant positive with found agonists: (ROR = 7.61, 95% CI: 6.37–9.08), dulaglutide 3.59, 3.03–4.27), liraglutide 15.59, 13.94–17.44) 2.09, 1.51–2.89). weak inverse observed metformin 0.58, 0.36–0.93). No other topiramate, dapagliflozin insulin glargine. Conclusion The study, based on FAERS database, suggests a agonists an increased risk. These findings underscore importance of further research continuous safety monitoring when prescribing these medications management.
Language: Английский
Citations
1
Biomarker Research, Journal Year: 2025, Volume and Issue: 13(1)
Published: March 27, 2025
Abstract Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as a primary first-line treatment for type 2 diabetes. This has raised concerns about their impact on cancer risk, spurring extensive research. review systematically examines the varied effects of GLP-1RAs risk different types tumors, including overall and specific cancers such thyroid, pancreatic, reproductive system, liver, colorectal cancers. The potential biological mechanisms underlying influence are complex, involving metabolic regulation, direct antitumor effects, immune modulation, epigenetic changes. A systematic comparison with other antidiabetic agents reveals notable differences in across drug classes. Additionally, critical factors that shape relationship between thoroughly analyzed, patient demographics, comorbidities, regimens, lifestyle factors, offering essential insights developing individualized protocols. Despite significant research progress, gaps remain. Future should prioritize elucidating molecular behind refining strategies, investigating early tumor prevention applications, assessing benefits non-diabetic populations, advancing development novel therapies, establishing robust safety monitoring frameworks, building precision medicine decision-making platforms. These efforts aim to establish roles prevention. treatment, thereby progress medicine.
Language: Английский
Citations
1
Biomolecules, Journal Year: 2024, Volume and Issue: 14(6), P. 687 - 687
Published: June 13, 2024
The increasing utilization of Glucagon-like Peptide-1 receptor agonists (GLP-1 RAs) in managing type 2 diabetes mellitus has raised interest regarding their impact on thyroid function. In fact, while these agents are well known for efficacy glycemic control and weight management, association with disorders requires clarification due to the complex interplay between hormones metabolic pathways. Thyroid dysfunction commonly co-occurs conditions such as obesity, suggesting a profound interconnection systems. This review aims contribute deeper understanding interaction GLP-1 RAs clarify safety diabetic patients disorders. By synthesizing existing evidence, this highlights that, despite various studies exploring topic, current evidence is inconclusive, conflicting results. It important note that drugs relatively recent, longer-term larger sample sizes likely needed draw clearer conclusions. Currently, no guidelines provide definitive directions clinical issue; however, it advisable include function tests routine screening patients, particularly those treated Ras, goal optimizing patient care management.
Language: Английский
Citations
8
Diabetes Obesity and Metabolism, Journal Year: 2025, Volume and Issue: unknown
Published: March 3, 2025
Abstract Aims GZR18, a novel long‐acting GLP‐1 receptor agonist, has demonstrated substantial metabolic improvements in diabetic and obese animal models. The present studies aimed to evaluate the safety, tolerability, pharmacokinetics (PK) pharmacodynamics (PD) of ascending dose GZR18 healthy American Chinese subjects. Materials Methods In these phases 1, randomized, double‐blind, placebo‐controlled, sequential, dose‐escalation US studies, adults with similar age were enrolled once‐weekly subcutaneous injection or placebo. included three cohorts male subjects (cohorts US‐1–3) six CN‐1–6, female), each specified target ranging from 1 50 μg/kg (1–10 for study 5–50 study). primary endpoints safety tolerability GZR18. Blood samples collected PK PD analysis before after dosing. A population was conducted ascertain whether there are ethnic differences between adults. Results exposure comparable subjects, geometric mean ratio two populations AUC 0‐t C max close 1. dose‐dependent increase 0–t occurred both populations. median time maximum plasma concentrations ( T ) ranged 72 96 h, 60 h half‐life approximately 7 days Evident body weight reduction observed treatment groups CN‐3–6 on Day 15, −1.25 −1.86 kg; −1.88% −3.11%). No deaths, serious adverse events hypoglycaemia reported. Decreased appetite nausea most frequently reported treatment‐emergent events, mild severity. profile generally consistent same class drugs. Conclusions demonstrates good profiles support its further clinical evaluation glycaemic control.
Language: Английский
Citations
0
Journal of Advanced Research, Journal Year: 2025, Volume and Issue: unknown
Published: April 1, 2025
Anorexia is a complex eating disorder influenced by genetic, environmental, psychological, and socio-cultural factors. Research into its molecular mechanisms neural circuits has deepened our understanding of pathogenesis. Recent advances in neuroscience, biology, genetics have revealed key circuit underlying anorexia. Aim review Clarify the peripheral central regulating various types anorexia, identify cytokines circuits, propose new strategies for treatment. Key scientific concepts animal models, including activity-induced, genetic mutation, inflammation-induced types, are explored their relevance to studying disorder. Anorexic behavior regulated cytokines, hormones (like GDF15, GLP-1, leptin), such as AgRP, serotonergic, dopaminergic, glutamatergic pathways. Disruptions these pathways, GABAergic signaling AgRP neurons 5-HT2C D2 receptors, contribute Potential therapies target neurotransmitter ghrelin GDF15-GFRAL pathway, offering insights treating immune responses, obesity.
Language: Английский
Citations
0
Frontiers in Endocrinology, Journal Year: 2024, Volume and Issue: 15
Published: Aug. 27, 2024
This study aimed to evaluate the effectiveness of thyroid fine needle aspiration cytology (FNAC) using a novel-cell preserving matrix called Cytomatrix in improving diagnostic accuracy for nodules.
Language: Английский
Citations
1
Cureus, Journal Year: 2024, Volume and Issue: unknown
Published: Sept. 18, 2024
Endometrial cancer (EC) is among the most common gynecological malignancies in developed countries and its occurrence has been increasing dramatically past few years. An in-depth knowledge of causes endometrial cancer, such as unopposed estrogen, insulin resistance, chronic inflammation, resulted suggestion numerous interventions to decrease this cancer. Recent research established a connection between obesity type 2 diabetes mellitus (T2DM) with higher chance developing suggesting that resistance key factor onset. Moreover, evidence from both epidemiological clinical studies indicates metformin, drug used treat diabetes, could possibly help prevention specific types The aim study explore possible impact glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) non-surgical management GLP-1 various functions produced when nutrients are consumed. Besides promoting release insulin, also suppresses secretion glucagon reduces appetite. fact receptors found different organs tissues brain, lung, pancreas, stomach, heart, endometrium GLP-1RAs have multiple functions. Prior shown it triggers apoptosis cells. Nevertheless, precise physiological function still needs be fully understood.
Language: Английский
Citations
1